PMN vs. APLM, MRKR, CASI, BCTX, JAN, DRRX, FBIO, IPA, SPRB, and VIRX
Should you be buying ProMIS Neurosciences stock or one of its competitors? The main competitors of ProMIS Neurosciences include Apollomics (APLM), Marker Therapeutics (MRKR), CASI Pharmaceuticals (CASI), BriaCell Therapeutics (BCTX), JanOne (JAN), DURECT (DRRX), Fortress Biotech (FBIO), ImmunoPrecise Antibodies (IPA), Spruce Biosciences (SPRB), and Viracta Therapeutics (VIRX). These companies are all part of the "pharmaceutical preparations" industry.
Apollomics (NASDAQ:APLM) and ProMIS Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, community ranking, valuation, earnings and institutional ownership.
Apollomics has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, ProMIS Neurosciences has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.
ProMIS Neurosciences' return on equity of 0.00% beat Apollomics' return on equity.
In the previous week, ProMIS Neurosciences had 4 more articles in the media than Apollomics. MarketBeat recorded 4 mentions for ProMIS Neurosciences and 0 mentions for Apollomics. Apollomics' average media sentiment score of 0.89 beat ProMIS Neurosciences' score of 0.00 indicating that ProMIS Neurosciences is being referred to more favorably in the news media.
Apollomics received 2 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users. However, 100.00% of users gave ProMIS Neurosciences an outperform vote while only 80.00% of users gave Apollomics an outperform vote.
19.1% of Apollomics shares are held by institutional investors. Comparatively, 50.1% of ProMIS Neurosciences shares are held by institutional investors. 10.3% of ProMIS Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Apollomics currently has a consensus target price of $2.00, indicating a potential upside of 502.05%. ProMIS Neurosciences has a consensus target price of $8.00, indicating a potential upside of 333.60%. Given ProMIS Neurosciences' higher probable upside, equities analysts plainly believe Apollomics is more favorable than ProMIS Neurosciences.
ProMIS Neurosciences has lower revenue, but higher earnings than Apollomics.
Summary
ProMIS Neurosciences beats Apollomics on 8 of the 14 factors compared between the two stocks.
Get ProMIS Neurosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProMIS Neurosciences Competitors List
Related Companies and Tools
